SLDB vs SLS: fair value comparison
Solid Biosciences Inc. and SELLAS Life Sciences Group, Inc. · Updated 2026-10-19
SLDB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SLS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SLDB currently ranks higher by quality score.
| SLDB | SLS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $5.53 | $9.98 |
| 12-month range | $3.93–$11.15 | $1.39–$15.46 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #266 of 301 Healthcare | #267 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: SLDB fair value analysis · SLS fair value analysis